GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Templates Inc (NAS:MTEM) » Definitions » Altman Z-Score

MTEM (Molecular Templates) Altman Z-Score : -24.90 (As of Dec. 14, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Molecular Templates Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -24.9 is in distress zone. This implies bankruptcy possibility in the next two years.

Molecular Templates has a Altman Z-Score of -24.90, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Molecular Templates's Altman Z-Score or its related term are showing as below:

MTEM' s Altman Z-Score Range Over the Past 10 Years
Min: -24.9   Med: -2.44   Max: 11.26
Current: -24.9

During the past 13 years, Molecular Templates's highest Altman Z-Score was 11.26. The lowest was -24.90. And the median was -2.44.


Molecular Templates Altman Z-Score Historical Data

The historical data trend for Molecular Templates's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Templates Altman Z-Score Chart

Molecular Templates Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.59 -0.99 -2.05 -8.92 -16.58

Molecular Templates Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.21 -14.25 -16.58 -23.90 -24.75

Competitive Comparison of Molecular Templates's Altman Z-Score

For the Biotechnology subindustry, Molecular Templates's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Templates's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Templates's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Molecular Templates's Altman Z-Score falls into.



Molecular Templates Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Molecular Templates's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1624+1.4*-17.246+3.3*-0.5805+0.6*0.1345+1.0*0.8796
=-24.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Jun. 2024:
Total Assets was $26.70 Mil.
Total Current Assets was $12.02 Mil.
Total Current Liabilities was $7.68 Mil.
Retained Earnings was $-460.42 Mil.
Pre-Tax Income was -8.097 + 0.572 + -3.959 + -4.153 = $-15.64 Mil.
Interest Expense was -0.038 + -0.031 + -0.039 + -0.031 = $-0.14 Mil.
Revenue was 0.189 + 10.924 + 6.639 + 5.732 = $23.48 Mil.
Market Cap (Today) was $2.63 Mil.
Total Liabilities was $19.59 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(12.016 - 7.68)/26.697
=0.1624

X2=Retained Earnings/Total Assets
=-460.417/26.697
=-17.246

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-15.637 - -0.139)/26.697
=-0.5805

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=2.634/19.586
=0.1345

X5=Revenue/Total Assets
=23.484/26.697
=0.8796

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Molecular Templates has a Altman Z-Score of -24.90 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Molecular Templates  (NAS:MTEM) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Molecular Templates Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Molecular Templates's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Templates Business Description

Traded in Other Exchanges
N/A
Address
9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
Executives
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Maurizio Voi officer: Chief Medical Officer 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sean Mclennan officer: CFO & Treasurer C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729
Kevin M. Lalande director, 10 percent owner 201 WEST 5TH STREET, AUSTIN TX 78701
Shv Management Services, Llc 10 percent owner FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701
Gabriela Gruia director C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Jason S. Kim officer: See Remarks 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Patrick G Enright 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Bakker Juliet Tammenoms 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
David Hirsch director, 10 percent owner C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Longitude Venture Partners Iii, L.p. 10 percent owner 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Scott D Morenstein director C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019